Will a Cineplex (TSX:CGX) Recovery Happen?

Cineplex (TSX:CGX) was once viewed as one of the best long-term plays on the market. Today, those investors are hoping for a Cineplex recovery.

| More on:
stock analysis

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

The COVID-19 pandemic has changed how businesses operate. Traditional brick-and-mortar retail have hastened their transition to e-commerce. Others, such as indoor dining and entertainment businesses have reverted to take-out and delivery only. While there is no doubt that those businesses will mount a complete recovery once the pandemic ends, the question is, when?

Cineplex (TSX:CGX) is the largest movie theatre chain in Canada. Those theatres remain largely shuttered due to the pandemic. Critics of Cineplex have long viewed the company’s traditional movie-and-popcorn business as a major risk for investors. That view stems from the growing availability of streaming options and devices, which has eliminated the exclusivity that movie theatres once offered. Now that theatres remain mostly closed and a second wave looms on the market, those concerns are only growing.

So far in 2020, Cineplex’s stock has plummeted over 85%. By way of comparison, the overall market is still in the red by 3% but it continues to creep up towards breaking even. Does this make Cineplex a great stock to buy at a discount on hopes of a grand Cineplex recovery? Not likely, and here’s a look at why.

Dismal results will mute any Cineplex recovery

Cineplex’s theatres continue to pivot between being partially and fully closed. As a result, attendance numbers remain dismal, and revenue numbers are a fraction of what they once were. Earlier this year, the company even suspended its once-impressive monthly dividend, hoarding that cash to remain afloat.

How bad were those results? In the most recent quarter (which was inclusive to June 30), Cineplex saw sales drop 95% year over year to just $22 million. Theatre attendance dropped to just 6,000 customers in the quarter, whereas in the same quarter last year, Cineplex welcomed 17 million customers.

Overall, Cineplex reported a net loss of $98 million in the quarter. In the same period last year, Cineplex reported earnings of $22 million.

Diversifying isn’t enough, is it?

Cineplex is an entertainment company, but most of its revenue is derived from its movie theatre business. The company has tried in recent years to diversify away from its movie-and-popcorn core, with some success. Cineplex’s Rec Room venues are a perfect example of this. The multi-configurable entertainment venues represent an interesting means to generate a separate revenue stream with plenty of growth potential.

Unfortunately, while the pandemic rages on, that growth potential is stalled, and Cineplex will continue to bleed cash. Other initiatives, such as Cineplex’s digital media sign business, are also being impacted. All of this needs to be considered for any sort of Cineplex recovery.

To be clear, the pandemic will end, and business will resume. The more pressing question is when, and what will that mean to Cineplex? Even before the pandemic, Cineplex was fighting a losing war with streaming services. Those services continue to offer content during the pandemic, including recent releases that were at one time viewed as Cineplex’s golden ticket (and justification for higher admission fees). An example of this is Mulan, which was released directly to streaming with a premium fee notched on. Further to this, as a result of the pandemic, some of the most highly anticipated movies of 2020 have been pushed back to 2021. This includes Wonder Woman 1984, Black Widow, No Time to Die, and Top Gun: Maverick.

In short, Cineplex’s issues will remain for at least another year and likely even longer, and, until then, its market will continue to erode.

Final thoughts

There are plenty of viable investment options on the market. Many of those options are now trading at a significant discount. That discount is well founded when it comes to Cineplex. Additionally, Cineplex no longer offers a dividend, and the company lacks any long-term growth prospects.

In my opinion, barring a miraculous Cineplex recovery, there are far better options to consider at the moment, many of which still offer a handsome dividend, too.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Demetris Afxentiou has no position in any of the stocks mentioned.

More on Coronavirus

Business success with growing, rising charts and businessman in background
Coronavirus

1 Growth Stock Every Canadian Investor Should Consider Right Now

This growth stock saw shares pop 10% on June 20, as one analyst stated there is a significant opportunity to…

Read more »

Aircraft wing plane
Coronavirus

Bombardier Stock Merge: What it Means for Investors

Bombardier (TSX:BBD.B) stock went through a reverse stock split on June 13, turning 25 shares into one in one swift…

Read more »

Aircraft wing plane
Coronavirus

Air Canada (TSX:AC) Stock: Ready to Take Off?

While Air Canada is handling what it can control really well, there are many worsening macro headwinds that will likely…

Read more »

rail train
Coronavirus

Bull or Bear: Why Analysts Changed Their Tune on Aecon Stock

Analysts had been champing at the bit for the construction company, but the tides have turned.

Read more »

Biotech stocks
Coronavirus

Is Bellus Health Stock Still a Buy After 30% Earnings Jump?

The biotech continues to make progress on obtaining FDA approval for its chronic-cough therapy.

Read more »

grow dividends
Coronavirus

Goodfood Stock Likely to Double in 2022!

Goodfood (TSX:FOOD) stock has had a huge rise and fall in the last few years. But at $1.85 a share,…

Read more »

grow dividends
Coronavirus

Canfor Stock Pops 5% as Sales Climb 15% YOY

Canfor (TSX:CFP) stock remained positive about its future in the global lumber market after profits climb 15% year over year.

Read more »

edit Safety First illustration
Coronavirus

2 Crash-Proof TSX Stocks I’d Buy With $5,000

These two TSX stocks have proven they can handle this economic downturn and likely will continue to be safe far…

Read more »